vs
Side-by-side financial comparison of Dole plc (DOLE) and Dexcom (DXCM). Click either name above to swap in a different company.
Dole plc is the larger business by last-quarter revenue ($2.3B vs $1.3B, roughly 1.8× Dexcom). Dexcom runs the higher net margin — 21.2% vs 0.2%, a 21.0% gap on every dollar of revenue. On growth, Dexcom posted the faster year-over-year revenue change (21.6% vs 10.5%). Over the past eight quarters, Dexcom's revenue compounded faster (12.0% CAGR vs 3.2%).
Dole plc is an Irish-American agricultural multinational corporation headquartered in Dublin, Ireland. The company is among the world's largest producers of fruit and vegetables, operating with 38,500 full-time and seasonal employees who supply some 300 products in 75 countries. Dole reported 2021 revenues of $6.5 billion.
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
DOLE vs DXCM — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.3B | $1.3B |
| Net Profit | $5.1M | $267.3M |
| Gross Margin | 6.8% | 62.9% |
| Operating Margin | 1.1% | 25.6% |
| Net Margin | 0.2% | 21.2% |
| Revenue YoY | 10.5% | 21.6% |
| Net Profit YoY | -64.6% | 153.6% |
| EPS (diluted) | $0.05 | $0.67 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.3B | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | $2.3B | $1.2B | ||
| Q2 25 | $2.4B | $1.2B | ||
| Q1 25 | $2.1B | $1.0B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $2.1B | $994.2M | ||
| Q2 24 | $2.1B | $1.0B |
| Q1 26 | — | $267.3M | ||
| Q4 25 | — | $267.3M | ||
| Q3 25 | $5.1M | $283.8M | ||
| Q2 25 | $10.0M | $179.8M | ||
| Q1 25 | $38.9M | $105.4M | ||
| Q4 24 | — | $151.7M | ||
| Q3 24 | $14.4M | $134.6M | ||
| Q2 24 | $80.1M | $143.5M |
| Q1 26 | — | 62.9% | ||
| Q4 25 | — | 62.9% | ||
| Q3 25 | 6.8% | 60.5% | ||
| Q2 25 | 9.0% | 59.5% | ||
| Q1 25 | 8.7% | 56.9% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | 8.0% | 59.7% | ||
| Q2 24 | 9.4% | 62.4% |
| Q1 26 | — | 25.6% | ||
| Q4 25 | — | 25.6% | ||
| Q3 25 | 1.1% | 20.1% | ||
| Q2 25 | 4.3% | 18.4% | ||
| Q1 25 | 3.2% | 12.9% | ||
| Q4 24 | — | 17.0% | ||
| Q3 24 | 2.3% | 15.3% | ||
| Q2 24 | 4.0% | 15.7% |
| Q1 26 | — | 21.2% | ||
| Q4 25 | — | 21.2% | ||
| Q3 25 | 0.2% | 23.5% | ||
| Q2 25 | 0.4% | 15.5% | ||
| Q1 25 | 1.9% | 10.2% | ||
| Q4 24 | — | 13.6% | ||
| Q3 24 | 0.7% | 13.5% | ||
| Q2 24 | 3.8% | 14.3% |
| Q1 26 | — | $0.67 | ||
| Q4 25 | — | $0.67 | ||
| Q3 25 | $0.05 | $0.70 | ||
| Q2 25 | $0.10 | $0.45 | ||
| Q1 25 | $0.41 | $0.27 | ||
| Q4 24 | — | $0.37 | ||
| Q3 24 | $0.15 | $0.34 | ||
| Q2 24 | $0.84 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $321.0M | $917.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | $2.7B |
| Total Assets | $4.5B | $6.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $917.7M | ||
| Q4 25 | — | $917.7M | ||
| Q3 25 | $321.0M | $1.8B | ||
| Q2 25 | $323.1M | $1.2B | ||
| Q1 25 | $261.0M | $904.9M | ||
| Q4 24 | — | $606.1M | ||
| Q3 24 | $266.4M | $621.2M | ||
| Q2 24 | $225.8M | $939.2M |
| Q1 26 | — | $2.7B | ||
| Q4 25 | — | $2.7B | ||
| Q3 25 | $1.4B | $2.7B | ||
| Q2 25 | $1.4B | $2.6B | ||
| Q1 25 | $1.3B | $2.3B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | $1.4B | $2.0B | ||
| Q2 24 | $1.4B | $2.4B |
| Q1 26 | — | $6.3B | ||
| Q4 25 | — | $6.3B | ||
| Q3 25 | $4.5B | $7.5B | ||
| Q2 25 | $4.7B | $7.3B | ||
| Q1 25 | $4.5B | $6.8B | ||
| Q4 24 | — | $6.5B | ||
| Q3 24 | $4.5B | $6.4B | ||
| Q2 24 | $4.4B | $6.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $87.4M | — |
| Free Cash FlowOCF − Capex | $66.5M | — |
| FCF MarginFCF / Revenue | 2.9% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | 17.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $13.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $294.0M | ||
| Q3 25 | $87.4M | $659.9M | ||
| Q2 25 | $18.3M | $303.0M | ||
| Q1 25 | $-78.8M | $183.8M | ||
| Q4 24 | — | $301.4M | ||
| Q3 24 | $101.0M | $199.5M | ||
| Q2 24 | $40.2M | $279.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $192.1M | ||
| Q3 25 | $66.5M | $579.4M | ||
| Q2 25 | $-1.0M | $208.9M | ||
| Q1 25 | $-131.6M | $96.8M | ||
| Q4 24 | — | $176.8M | ||
| Q3 24 | $79.9M | $88.3M | ||
| Q2 24 | $22.8M | $213.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 15.3% | ||
| Q3 25 | 2.9% | 47.9% | ||
| Q2 25 | -0.0% | 18.1% | ||
| Q1 25 | -6.3% | 9.3% | ||
| Q4 24 | — | 15.9% | ||
| Q3 24 | 3.9% | 8.9% | ||
| Q2 24 | 1.1% | 21.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 8.1% | ||
| Q3 25 | 0.9% | 6.7% | ||
| Q2 25 | 0.8% | 8.1% | ||
| Q1 25 | 2.5% | 8.4% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | 1.0% | 11.2% | ||
| Q2 24 | 0.8% | 6.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.10× | ||
| Q3 25 | 17.12× | 2.33× | ||
| Q2 25 | 1.84× | 1.69× | ||
| Q1 25 | -2.02× | 1.74× | ||
| Q4 24 | — | 1.99× | ||
| Q3 24 | 7.01× | 1.48× | ||
| Q2 24 | 0.50× | 1.95× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
